uracil has been researched along with Dihydropyrimidine Dehydrogenase Deficiency in 45 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Dihydropyrimidine Dehydrogenase Deficiency: An autosomal recessive disorder affecting DIHYDROPYRIMIDINE DEHYDROGENASE and causing familial pyrimidinemia. It is characterized by thymine-uraciluria in homozygous deficient patients. Even a partial deficiency in the enzyme leaves individuals at risk for developing severe 5-FLUOROURACIL-associated toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 7.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 7.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy." | 3.81 | Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 3.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "The uracil AUC(0>180) was 31." | 2.76 | Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. ( Guchelaar, HJ; Maring, JG; Theeuwes-Oonk, B; van Kuilenburg, AB; van Staveren, MC, 2011) |
| " Individualized dosing for these patients can reduce the incidence of severe fluoropyrimidine-related toxicity." | 2.72 | Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options? ( Beijnen, JH; Cats, A; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Knikman, JE, 2021) |
| "DPD-deficient cancer patients may be at risk of severe and sometimes lethal toxicity after the administration of 5-FU." | 2.48 | [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil]. ( Dołegowska, B; Ostapowicz, A, 2012) |
| "8% of DPYD variant carriers died due to FP-TOX compared to 0% in the group receiving DPYD genotype-guided dosing of FP." | 1.91 | Implementation and clinical benefit of DPYD genotyping in a Danish cancer population. ( Bergmann, TK; Damkier, P; Ewertz, M; Feddersen, S; Fruekilde, PBN; Holm, HS; Paulsen, NH; Pfeiffer, P; Qvortrup, C, 2023) |
| "Since 2019, DPD deficiency testing, based on uracilemia, is mandatory in France and recommended in Europe before initiating fluoropyrimidine-based regimens." | 1.91 | Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping. ( Ciccolini, J; Derain, L; Guitton, J; Launay, M; Parant, F; Royer, B; Thomas, F, 2023) |
| " Although the evidence for genotype-directed dosing of fluoropyrimidines is substantial, the level of evidence supporting plasma uracil levels to predict DPD activity in clinical practice is limited." | 1.72 | Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study. ( Beijnen, JH; Cats, A; de Man, FM; de Vries, N; de With, M; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Imholz, ALT; Knikman, J; Lunenburg, CATC; Maring, JG; Mathijssen, RHJ; Meulendijks, D; Modak, A; Pluim, D; Rosing, H; Schellens, JHM; Swen, JJ; van Kuilenburg, ABP; van Schaik, RHN; van Staveren, MC, 2022) |
| " Tolerance was good and 5-FU dosing was next shifted to 25% reduction, then further shifted to normal dosing at the 5th course, with still no sign for drug-related toxicities." | 1.72 | Renal impairment and DPD testing: Watch out for false-positive results! ( Carriat, L; Ciccolini, J; Quaranta, S; Rony, M; Solas, C, 2022) |
| "However, the best strategy to identify DPD deficiency in End Stage Renal Disease (ESRD) patients is unknown." | 1.62 | Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results. ( Gaible, C; Loriot, MA; Narjoz, C; Pallet, N; Roueff, S, 2021) |
| "Uracil was superior to the dihydrouracil/uracil ratio as a predictor of severe toxicity." | 1.46 | Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. ( Aliev, A; Beijnen, JH; Cats, A; de Boer, A; de Vries, N; Deenen, MJ; Henricks, LM; Jacobs, BAW; Mandigers, CMPW; Meulendijks, D; Rosing, H; Schellens, JHM; Soesan, M; van Werkhoven, E, 2017) |
| "5-Fluorouracil (5-FU) is a mainstay for treating various solid tumours in adults, including digestive and head and neck cancers." | 1.37 | 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. ( Ciccolini, J; Cordier, PY; Lacarelle, B; Mercier, C; Nau, A; Oliver, M; Peytel, E, 2011) |
| " In this work, an artificial receptor in the format of molecularly imprinted polymer (MIP) brush 'grafted to' the surface of sol-gel immobilized on cost-effective homemade solid-phase microextraction (SPME) fibers, individually imprinted with either of Ura and 5FU, was used in combination with a voltammetric sensor duly modified with the same MIP." | 1.35 | Ultratrace analysis of uracil and 5-fluorouracil by molecularly imprinted polymer brushes grafted to silylated solid-phase microextraction fiber in combination with complementary molecularly imprinted polymer-based sensor. ( Patel, AK; Prasad, BB; Sharma, PS; Singh, M; Srivastava, S; Tiwari, K, 2009) |
| "We strongly suspected a DPD deficiency from the result of urinary pyrimidine analysis." | 1.35 | [A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration]. ( Doi, Y; Endo, Y; Ishizuka, S; Kai, K; Matsumoto, Y; Morikawa, T; Nabeyama, A; Nagahiro, W; Nakashima, A; Nobuhisa, T; Sato, S; Watanabe, T; Yamada, T; Yoshida, K, 2008) |
| "We report a rare patient with a DPD deficiency." | 1.33 | [A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency]. ( Arai, K; Hashimoto, T; Hiruma, K; Iwasaki, Y; Matsumoto, H; Saze, Z; Takahashi, K; Yamaguchi, T; Yamashita, Y; Yasutome, M, 2006) |
| "A physiologically based pharmacokinetic (PBPK) model to simulate the plasma concentration and 13CO2 exhalation after [2-13C]uracil administration to DPD-suppressed dogs was developed." | 1.33 | Pharmacokinetic modelling of [2-13C]uracil metabolism in normal and DPD-deficient dogs. ( Hirao, Y; Inada, M; Itose, M; Koga, T; Kunizaki, J; Sato, H; Shimizu, T, 2006) |
| "Thus, DPD deficiency may feature prominent brain abnormalities involving the cerebral white matter and brainstem." | 1.32 | Head imaging abnormalities in dihydropyrimidine dehydrogenase deficiency. ( Barkovich, AJ; Enns, GM; Manning, M; Sanger, T; van Gennip, AH; van Kuilenburg, AB; Witt, DR, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (28.89) | 29.6817 |
| 2010's | 19 (42.22) | 24.3611 |
| 2020's | 13 (28.89) | 2.80 |
| Authors | Studies |
|---|---|
| Gaible, C | 1 |
| Narjoz, C | 3 |
| Loriot, MA | 5 |
| Roueff, S | 1 |
| Pallet, N | 1 |
| de With, M | 1 |
| Knikman, J | 1 |
| de Man, FM | 1 |
| Lunenburg, CATC | 1 |
| Henricks, LM | 4 |
| van Kuilenburg, ABP | 1 |
| Maring, JG | 4 |
| van Staveren, MC | 4 |
| de Vries, N | 3 |
| Rosing, H | 3 |
| Beijnen, JH | 4 |
| Pluim, D | 1 |
| Modak, A | 2 |
| Imholz, ALT | 1 |
| van Schaik, RHN | 1 |
| Schellens, JHM | 2 |
| Gelderblom, H | 4 |
| Cats, A | 3 |
| Guchelaar, HJ | 5 |
| Mathijssen, RHJ | 1 |
| Swen, JJ | 1 |
| Meulendijks, D | 3 |
| Menestrina Dewes, M | 1 |
| Cé da Silva, L | 1 |
| Fazenda Meireles, Y | 1 |
| Viana de Freitas, M | 1 |
| Frank Bastiani, M | 1 |
| Feltraco Lizot, L | 1 |
| Zilles Hahn, R | 1 |
| Venzon Antunes, M | 1 |
| Linden, R | 1 |
| Carriat, L | 1 |
| Quaranta, S | 3 |
| Solas, C | 2 |
| Rony, M | 1 |
| Ciccolini, J | 7 |
| Maillard, M | 1 |
| Launay, M | 6 |
| Royer, B | 6 |
| Guitton, J | 5 |
| Gautier-Veyret, E | 1 |
| Broutin, S | 1 |
| Tron, C | 1 |
| Le Louedec, F | 1 |
| Richard, D | 1 |
| Alarcan, H | 1 |
| Haufroid, V | 4 |
| Tafzi, N | 1 |
| Schmitt, A | 2 |
| Etienne-Grimaldi, MC | 5 |
| Thomas, F | 8 |
| Liu, N | 1 |
| Sun, Q | 1 |
| Boyer, JC | 4 |
| Paulsen, NH | 1 |
| Pfeiffer, P | 1 |
| Ewertz, M | 1 |
| Fruekilde, PBN | 1 |
| Feddersen, S | 1 |
| Holm, HS | 1 |
| Bergmann, TK | 1 |
| Qvortrup, C | 1 |
| Damkier, P | 1 |
| Derain, L | 1 |
| Parant, F | 1 |
| Bolzacchini, E | 1 |
| Luchena, G | 1 |
| Giordano, M | 1 |
| Nasser, Y | 1 |
| Tholance, Y | 1 |
| Dellinger, S | 1 |
| Gonzalo, P | 1 |
| Delavenne, X | 1 |
| Marin, C | 1 |
| Krache, A | 1 |
| Palmaro, C | 1 |
| Lucas, M | 1 |
| Hilaire, V | 1 |
| Ugdonne, R | 1 |
| De Victor, B | 1 |
| Lacarelle, B | 3 |
| García-González, X | 1 |
| Kaczmarczyk, B | 1 |
| Abarca-Zabalía, J | 1 |
| García-Alfonso, P | 1 |
| Robles, L | 1 |
| Pachón, V | 1 |
| Vaz, Á | 1 |
| Salvador-Martín, S | 1 |
| Sanjurjo-Sáez, M | 1 |
| López-Fernández, LA | 1 |
| Knikman, JE | 1 |
| Jacobs, BAW | 1 |
| Aliev, A | 1 |
| Deenen, MJ | 1 |
| van Werkhoven, E | 1 |
| de Boer, A | 1 |
| Mandigers, CMPW | 1 |
| Soesan, M | 1 |
| Milano, G | 3 |
| Barin-Le-Guellec, C | 1 |
| Picard, N | 1 |
| Becquemont, L | 1 |
| Verstuyft, C | 1 |
| Bobin-Dubigeon, C | 1 |
| Harle, A | 1 |
| Paci, A | 1 |
| Poinsignon, V | 1 |
| Evrard, A | 1 |
| Hennart, B | 1 |
| Broly, F | 1 |
| Fonrose, X | 1 |
| Lafay-Chebassier, C | 1 |
| Wozny, AS | 1 |
| Masskouri, F | 1 |
| Robert, J | 1 |
| Ostapowicz, A | 1 |
| Dołegowska, B | 1 |
| Yeung, CW | 1 |
| Yau, MM | 1 |
| Ma, CK | 1 |
| Siu, TS | 1 |
| Tam, S | 1 |
| Lam, CW | 1 |
| Cunha-Junior, GF | 1 |
| De Marco, L | 1 |
| Bastos-Rodrigues, L | 1 |
| Bolina, MB | 1 |
| Martins, FL | 1 |
| Pianetti, GA | 1 |
| Cesar, IC | 1 |
| Coelho, LG | 1 |
| Opdam, F | 1 |
| van Kuilenburg, AB | 7 |
| Hennebelle, I | 1 |
| Delmas, C | 1 |
| Lochon, I | 1 |
| Dhelens, C | 1 |
| Garnier Tixidre, C | 1 |
| Bonadona, A | 1 |
| Penel, N | 1 |
| Goncalves, A | 1 |
| Delord, JP | 1 |
| Toulas, C | 1 |
| Chatelut, E | 1 |
| Meijer, J | 2 |
| Punt, CJ | 1 |
| de Jong, RS | 1 |
| Kuilenburg, ABPV | 1 |
| Tanck, MWT | 1 |
| Dobritzsch, D | 1 |
| Zoetekouw, L | 1 |
| Dekkers, LL | 1 |
| Roelofsen, J | 1 |
| Meinsma, R | 1 |
| Wymenga, M | 1 |
| Kulik, W | 1 |
| Büchel, B | 1 |
| Hennekam, RCM | 1 |
| Largiadèr, CR | 1 |
| Jacobs, BA | 1 |
| Schellens, JH | 1 |
| Ben Fredj, R | 1 |
| Gross, E | 2 |
| Ben Ahmed, S | 1 |
| Hassine, H | 1 |
| Saguem, S | 1 |
| Prasad, BB | 1 |
| Tiwari, K | 1 |
| Singh, M | 1 |
| Sharma, PS | 1 |
| Patel, AK | 1 |
| Srivastava, S | 1 |
| Mounier-Boutoille, H | 1 |
| Boisdron-Celle, M | 2 |
| Cauchin, E | 1 |
| Galmiche, JP | 1 |
| Morel, A | 2 |
| Gamelin, E | 2 |
| Matysiak-Budnik, T | 1 |
| Weidensee, S | 1 |
| Goettig, P | 1 |
| Bertone, M | 1 |
| Haas, D | 1 |
| Magdolen, V | 1 |
| Kiechle, M | 1 |
| Meindl, A | 1 |
| Cordier, PY | 1 |
| Nau, A | 1 |
| Oliver, M | 1 |
| Mercier, C | 1 |
| Peytel, E | 1 |
| Theeuwes-Oonk, B | 1 |
| Wettergren, Y | 1 |
| Carlsson, G | 1 |
| Odin, E | 1 |
| Gustavsson, B | 1 |
| Stroomer, AE | 1 |
| Van Lenthe, H | 1 |
| Abeling, NG | 1 |
| Van Gennip, AH | 3 |
| Mattison, LK | 1 |
| Ezzeldin, H | 1 |
| Carpenter, M | 1 |
| Johnson, MR | 1 |
| Diasio, RB | 1 |
| Enns, GM | 1 |
| Barkovich, AJ | 1 |
| Manning, M | 1 |
| Sanger, T | 1 |
| Witt, DR | 1 |
| Inada, M | 2 |
| Hirao, Y | 2 |
| Koga, T | 2 |
| Itose, M | 2 |
| Kunizaki, J | 2 |
| Shimizu, T | 2 |
| Sato, H | 2 |
| Branca, MA | 1 |
| Al-Sanna'a, NA | 1 |
| Atrak, TM | 1 |
| Abdul-Jabbar, MA | 1 |
| Schmidt, C | 1 |
| Hofmann, U | 1 |
| Kohlmüller, D | 1 |
| Mürdter, T | 1 |
| Zanger, UM | 1 |
| Schwab, M | 1 |
| Hoffmann, GF | 1 |
| Hashimoto, T | 1 |
| Arai, K | 1 |
| Iwasaki, Y | 1 |
| Saze, Z | 1 |
| Takahashi, K | 1 |
| Yamaguchi, T | 1 |
| Matsumoto, H | 1 |
| Yasutome, M | 1 |
| Hiruma, K | 1 |
| Yamashita, Y | 1 |
| Remaud, G | 1 |
| Traore, S | 1 |
| Poirier, AL | 1 |
| Gamelin, L | 1 |
| Kai, K | 1 |
| Endo, Y | 1 |
| Yoshida, K | 1 |
| Morikawa, T | 1 |
| Nobuhisa, T | 1 |
| Watanabe, T | 1 |
| Matsumoto, Y | 1 |
| Yamada, T | 1 |
| Doi, Y | 1 |
| Nakashima, A | 2 |
| Nagahiro, W | 1 |
| Ishizuka, S | 1 |
| Sato, S | 1 |
| Nabeyama, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving the Safety of Fluoropyrimidine-based Chemotherapy by Combined DPYD Genotype-guided and DPD Phenotype-guided Dose Individualization: The ALPE2U Study[NCT04194957] | 1,440 participants (Anticipated) | Interventional | 2020-01-15 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for uracil and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2021 |
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2018 |
[Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Topics: Antineoplastic Agents; Biomarkers; Breath Tests; Capecitabine; Comorbidity; Deoxycytidine; Dihydropy | 2012 |
2 trials available for uracil and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.
Topics: Administration, Oral; Case-Control Studies; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouraci | 2016 |
Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency.
Topics: Administration, Oral; Adult; Aged; Dihydropyrimidine Dehydrogenase Deficiency; Female; Humans; Male; | 2011 |
40 other studies available for uracil and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results.
Topics: Case-Control Studies; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP) | 2021 |
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Evaluation of the Tasso-SST® capillary blood microsampling device for the measurement of endogenous uracil levels.
Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Dihydropyrimidine Dehydrogenase Defici | 2022 |
Renal impairment and DPD testing: Watch out for false-positive results!
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2022 |
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Quantitation of Pyrimidine in Urine by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Biomarkers; Chromatography, Liquid; Dihydropyrimidine Dehydrogenase Deficiency; Humans; Pyrimidines; | 2022 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans | 2023 |
Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Denmark; Dihydropyrimidine Dehydrogenase Deficiency; | 2023 |
Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2023 |
Safety Report of TAS-102 in a Patient With Reduced DPD Activity.
Topics: Aged; Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase | 2019 |
Delaying Centrifugation and Freezing by Adding a Dihydropyrimidine Dehydrogenase Inhibitor Such as Gimeracil to Blood Sample Is Not a Valid Option to Simplify the Preanalytic Step for the Screening of Dihydropyrimidine Dehydrogenase Deficiency Using Uraci
Topics: Centrifugation; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Free | 2020 |
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Chromatog | 2020 |
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Computer Simulation; | 2020 |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; | 2017 |
PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine.
Topics: Antibiotics, Antineoplastic; Biomarkers; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; H | 2017 |
[5-FU: At last!]
Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Fl | 2019 |
Fluoropyrimidines and DPD testing: is there truly an inexorable link?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2019 |
Diagnosis of dihydropyrimidinase deficiency in a Chinese boy with dihydropyrimidinuria.
Topics: Child, Preschool; China; Dihydropyrimidine Dehydrogenase Deficiency; Hong Kong; Humans; Male; Metabo | 2013 |
(13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breath Tests; Carbon Isotopes; Dihy | 2013 |
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2015 |
Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
Topics: Adult; Antimetabolites, Antineoplastic; Biotransformation; Dihydropyrimidine Dehydrogenase Deficienc | 2016 |
Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
Topics: Amino Acid Substitution; Codon, Nonsense; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil | 2016 |
Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma.
Topics: Chromatography, High Pressure Liquid; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehy | 2016 |
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Chromatography, High Pressure Liquid; Colo | 2009 |
Ultratrace analysis of uracil and 5-fluorouracil by molecularly imprinted polymer brushes grafted to silylated solid-phase microextraction fiber in combination with complementary molecularly imprinted polymer-based sensor.
Topics: Benzenesulfonates; Binding Sites; Dihydropyrimidine Dehydrogenase Deficiency; Fluorouracil; Humans; | 2009 |
Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydropyrimidine Dehydrog | 2010 |
A mild phenotype of dihydropyrimidine dehydrogenase deficiency and developmental retardation associated with a missense mutation affecting cofactor binding.
Topics: Amino Acid Sequence; Child; Creatinine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil De | 2011 |
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Dihydropyrimidine Dehydrogenase Deficiency; Electroenc | 2011 |
Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
New insights in dihydropyrimidine dehydrogenase deficiency: a pivotal role for beta-aminoisobutyric acid?
Topics: Aminoisobutyric Acids; beta-Alanine; Brain Diseases, Metabolic, Inborn; Dihydropyrimidine Dehydrogen | 2004 |
Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test.
Topics: Antimetabolites, Antineoplastic; Breath Tests; Carbon Dioxide; Carbon Isotopes; Chromatography, High | 2004 |
Head imaging abnormalities in dihydropyrimidine dehydrogenase deficiency.
Topics: Brain; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Female; Humans; Infant; Magnetic R | 2004 |
Relationships among plasma [2-(13)C]uracil concentrations, breath (13)CO(2) expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and dpd-deficient dogs.
Topics: Administration, Oral; Animals; Breath Tests; Bromouracil; Carbon Dioxide; Carbon Isotopes; Dihydropy | 2005 |
BiDil raises questions about race as a marker.
Topics: Biomarkers; Black People; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihy | 2005 |
Dihydropyrimidine dehydrogenase deficiency presenting at birth.
Topics: Age of Onset; Antimetabolites; Binding Sites; Digestive System Abnormalities; Dihydropyrimidine Dehy | 2005 |
Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high-pressure liquid chromatography-electrospray ionization tandem mass spectrometry.
Topics: Adolescent; beta-Alanine; Child; Child, Preschool; Chromatography, High Pressure Liquid; Dihydropyri | 2005 |
[A case of recurrent gastric cancer with dihydropyrimidine dehydrogenase (DPD) deficiency].
Topics: Adult; Anorexia; Antimetabolites, Antineoplastic; Bone Neoplasms; Cerebral Hemorrhage; Dihydropyrimi | 2006 |
5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Def | 2007 |
Pharmacokinetic modelling of [2-13C]uracil metabolism in normal and DPD-deficient dogs.
Topics: Administration, Oral; Animals; Breath Tests; Carbon Dioxide; Carbon Isotopes; Computer Simulation; D | 2006 |
[A case of dihydropyrimidine dehydrogenase (DPD) deficiency with severe side effects from UFT/Uzel administration].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dihydropyrimidine Dehy | 2008 |